Medical healthcare providers can find more information and tools here to support patient care and research into innovative medicines.
We believe in the power of science in addressing some of the most challenging diseases of our time. Along with our long history of developing life-saving medicines, we have a promising pipeline that will shape the next generation of treatment options across various indications in four therapeutic areas.
Bristol Myers Squibb is active in four therapeutic areas
Bristol Myers Squibb (BMS) is a leader in the field of oncology, with a comprehensive portfolio of both approved and investigational medicines.
Our focus lies in four key areas:
- Through our focus on tumour biology and translational research, we identify the right treatments for suitable patients at the right time.
- We are exploring new therapies that have the potential to change existing standards of care.
- We are exploring opportunities for patients who cannot currently be treated using checkpoint inhibitors.
- In IO-responsive tumours, we try to increase, deepen, and/or prolong the body's natural response to recognise and destroy cancer cells.
Living with an immune-mediated disease is a debilitating reality for hundreds of millions of people around the world. While there has been progress with research and therapeutic options, patients may not respond to available treatments. Many continue to endure chronic symptoms and disease progression that can take a toll on their physical, emotional and social well-being, making simple tasks and daily life a challenge.
At Bristol Myers Squibb, we are pursuing pathbreaking science in Immunology to deliver meaningful solutions that address unmet needs in rheumatology, gastroenterology, dermatology and neurology. Our goal is to restore some of what immune-mediated diseases have taken away—empowering patients and their loved ones to take back their lives.
Hematology is a fundamental pillar of Bristol Myers Squibb in which we have made significant progress.
We are determined to maintain our leading role and expertise in developing breakthrough therapies to treat patients with malignant and benign hematological disorders.
The focus of the company lies on myeloma, lymphoma, leukemia and myeloid diseases (such as myelodysplastic syndrome, beta-thalassemia and myeloproliferative neoplasms).
Every day, we are committed to developing innovative treatments for patients with cardiovascular diseases.
Our focus is both chronic and acute heart failure, with particular interest in patients with heart failure with preserved ejection fraction.
Medical Information and Services
Medical Information Contact Centre and reporting side effects or product quality complaints.
Visit our international website to report side effects or submit product quality complaints and questions about medical information in other countries.
Clinical studies are essential in developing new medicines. BMS Belgium is currently running 95 active clinical studies.
Learn more about how we research and develop experimental medicines for patients.
Bristol Myers Squibb is committed to advancing science by supporting new, independent research that addresses unmet needs related to our products and therapeutic areas.
We are open to requests from independent researchers who support our objective.
We maintain the highest standards of integrity and continue to increase our level of transparency so that we can share information with our patients, colleagues, and shareholders.